Login / Signup

Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis.

Giovanni CaocciOlga MulasDaniela MantovaniAlessandro CostaAndrea GaliziaLuca BarabinoMarianna GrecoRoberta MurruGiorgio La Nasa
Published in: Annals of hematology (2021)
Keyphrases
  • coronavirus disease
  • sars cov
  • immune response